Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Merck Healthcare KGaA
Sponsor

Merck Healthcare KGaA

Germany Frankfurter Strasse 250, 64293 Darmstadt, Germany

About the sponsor

Clinical activity spans advanced solid tumors, non-small cell lung cancer, lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, epithelial ovarian cancer, and colorectal cancer, with additional interest in metastatic and locally advanced unresectable tumors.

  • METex14 skipping alterations and MET amplification
  • EGFR-mutated lung cancer
  • CEACAM5-targeted solid tumor programs
  • DNA damage response and topoisomerase 1-based combinations

Research also includes head and neck squamous cell carcinoma, reflecting a broad oncology portfolio across thoracic, gastrointestinal, and upper aerodigestive malignancies.

About Specializations

Merck Healthcare KGaA runs clinical trials in conditions such as Cutaneous lupus erythematosus, Systemic lupus erythematosus, Chronic cutaneous lupus erythematosus, Subacute cutaneous lupus erythematosus, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

17 clinical trials

Colorectal cancer metastatic

Recruiting

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

Systemic lupus erythematosus+3

Recruiting

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Chronic cutaneous lupus erythematosus+2

Recruiting

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Myasthenia gravis

Recruiting

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Merck Healthcare KGaA

Neurofibromatosis+1

Recruiting

A study of mirdametinib for infants and toddlers under 24 months of age with neurofibromatosis type 1 associated plexiform neurofibromas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:Merck Healthcare KGaA

Pancreatic carcinoma metastatic

Not yet recruiting

Study of M9140 for Patients With Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Systemic lupus erythematosus+1

Not recruiting

Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
  • Sponsor:Merck Healthcare KGaA

Non-small cell lung cancer metastatic

Not recruiting

Study of M9140 for Patients with Advanced Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Metastatic gastric cancer

Not recruiting

Study of M9140 for Patients with Advanced Stomach Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Squamous cell carcinoma of head and neck

Not recruiting

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Systemic lupus erythematosus+3

Not recruiting

Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.